Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 1997

View Archived Issues

Company Profile: Miravant

Agouron: Annual Report 1997

Gensia Laboratories receives generic approval

Medarex reports novel method for treating infectious disease

Therapeutic Antibodies: Q3 1997 highlights

Gene causing familial Mediterranean fever identified, available for licensing

NIH offers licenses for method for diagnosing alpha-thalassemia

FDA clears IND for ImmuLogic's cocaine vaccine

OR-1384 at least equieffective to 5-ASA in acute and chronic colitis in mice

Genta to evaluate G-3139 in U.S. prostate cancer trial

FR-173657 effective in models of kinin-dependent inflammation

Sugen initiates phase II prostate cancer trial with SU-101

Preclinical results reported for JTE-522, a selective COX-2 inhibitor

VIMRx: Q3 1997 highlights

Oncaspar approved in Canada

New tacrine analogue designated for further development

DuPont Merck develops novel CRF antagonists

SKB reveals selective inhibitors of bacterial enzyme

Endothelin-modulating compounds developed at Texas Biotechnology

Chiroscience files MAA for Chirocaine

OncoVax-P clinical data reported at scientific meeting

Candesartan introduced in U.K., Germany

Therapeutic potential of PC-SOD evaluated preclinically

Sequence-specific anti-HIV activity reported for the oligodeoxynucleotide SA-1042

PMPA prodrug with favorable biological/pharmaceutical properties

Cyberonics receives EU approval for expanded use of VNS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...